Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Ambitious AB Science Gets Masitinib Win For Severe Asthma

Fri, 11/08/2019 - 6:14am

Plagued by concerns on the integrity of data and compliance issues with its clinical practices, the French firm still believes...

      Related Stories 

Dengvaxia Beater? Promising But Mixed Results For Takeda’s Dengue Contender

Thu, 11/07/2019 - 5:13pm

Long-anticipated findings for Japanese firm’s dengue vaccine show efficacy rates above its only rival, including in those not previously exposed...

      Related Stories 

HIV PrEP Patent Dispute Escalates As HHS Files Suit Against Gilead

Thu, 11/07/2019 - 4:32pm

Trump administration wants the HIV drug maker to license HHS patents related to pre-exposure prophylaxis. Lawsuit follows Gilead’s request in...

      Related Stories 

Teva Turnaround Hung Up By The Uncertain Cost Of Settling Opioid Cases

Thu, 11/07/2019 - 12:09pm

Teva's business appears to be stabilizing but the company needs to resolve outstanding opioid liability litigation. CEO Schultz said he...

      Related Stories 

Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market

Thu, 11/07/2019 - 11:12am

Truxima will launch in the US on 11 November for oncology indications at a 10% discount to the list price...

      Related Stories 

ObsEva Gives Up On IVF Drug As Phase III Study Fails

Thu, 11/07/2019 - 8:40am

Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a...

      Related Stories 

Executives On The Move: New Arrivals In Commercial For Exopharm And Primex, And A Departure At Grupo Biotoscana

Thu, 11/07/2019 - 4:09am

For Exopharm, an Australian regenerative medicine firm, a new chief commercial officer, and for Primex Pharmaceuticals, a global anesthesia products...

      Related Stories 

ASH First Look: CAR-T Therapies Against BCMA, CD19 And More

Wed, 11/06/2019 - 6:03pm

CAR-T therapies from Janssen, Celgene and others will get a lot of attention at the annual hematology meeting, including candidates...

      Related Stories 

Sun Allies With AZ To Drive China Oncology Push

Wed, 11/06/2019 - 4:16pm

India's Sun Pharma joins hands with AstraZeneca to commercialize certain 'ready to use' oncology therapies in China, hoping to capitalize...

      Related Stories 

Asia Deal Watch: Ambrx, NovoCodex Partner On Second ADC Candidate, For CD70-Positive Cancers

Wed, 11/06/2019 - 2:01pm

Deal follows 2013 pact between Ambrx and NovoCodex parent Zhejiang Medicine for HER2-positive-directed ADC. Astellas teams with Pandion on pancreatic...

      Related Stories 

Horizon Ramps Teprotumumab Launch Plans Into High Gear

Wed, 11/06/2019 - 11:49am

With US FDA action on teprotumumab anticipated in March, Horizon has assembled a 100-person commercial team to begin educating physicians...

      Related Stories 

Evotec, Vifor JV To Fight Kidney Disease

Wed, 11/06/2019 - 7:34am

Evotec’s CSO says its new joint venture with Vifor will use patient-driven data to identify and develop targeted therapies to...

      Related Stories 

Cellular Stress Targeted By Black Belt TX-Praxis Biotech Partnership

Wed, 11/06/2019 - 6:52am

A strategic partnership active in the hot area of understanding the tumor micro-environment in order to develop new cancer drugs...

      Related Stories 

GW Pharma Bets On Europe For Epidiolex Growth

Wed, 11/06/2019 - 6:00am

The company expects the first ever plant-derived cannabinoid to be authorized in Europe to benefit from having already been used...

      Related Stories 

UK Biotech Ervaxx Launches With Focus On ‘Dark Antigens’

Wed, 11/06/2019 - 3:33am

Melanoma is first target for company developing cancer vaccines and T-cell receptor immunotherapies.

      Related Stories 

Mehta Analysis: Who Will Speak Out As Regulators Are Politicized?

Wed, 11/06/2019 - 2:05am

In his latest opinion piece, Viren Mehta fears the impact that ideologically motivated and protectionist actions around the world will...

      Related Stories 

Pages